NO20006087L - Fremgangsmåter for å öke nivåer av acetylcholin - Google Patents

Fremgangsmåter for å öke nivåer av acetylcholin

Info

Publication number
NO20006087L
NO20006087L NO20006087A NO20006087A NO20006087L NO 20006087 L NO20006087 L NO 20006087L NO 20006087 A NO20006087 A NO 20006087A NO 20006087 A NO20006087 A NO 20006087A NO 20006087 L NO20006087 L NO 20006087L
Authority
NO
Norway
Prior art keywords
acetylcholine
methods
increase levels
compound
formula
Prior art date
Application number
NO20006087A
Other languages
English (en)
Other versions
NO20006087D0 (no
Inventor
Henry Uhlman Bryant
Michele Anette Glinn
Steven Mark Paus
Xin Wu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20006087L publication Critical patent/NO20006087L/no
Publication of NO20006087D0 publication Critical patent/NO20006087D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Den foreliggende oppfinnelsen vedrører en fremgangsmåte for å øke nivåer av acetylcholin i pattedyr omfattende å administrere til et pattedyr som har behov for dette, en effektiv mengde av en forbindelse med formel (I), og eventuelt en AChE hemmer. ORJ Oppfinnelsen omfatter andvendelse av forbindelse med formel I for fremstilling av et medikament til behandling av alzheimers sykdom.
NO20006087A 1998-06-16 2000-11-30 Fremgangsmåter for å öke nivåer av acetylcholin NO20006087D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8948998P 1998-06-16 1998-06-16
PCT/US1999/012525 WO1999065489A1 (en) 1998-06-16 1999-06-04 Methods for increasing levels of acetylcholine

Publications (2)

Publication Number Publication Date
NO20006087L true NO20006087L (no) 2000-11-30
NO20006087D0 NO20006087D0 (no) 2000-11-30

Family

ID=22217929

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006087A NO20006087D0 (no) 1998-06-16 2000-11-30 Fremgangsmåter for å öke nivåer av acetylcholin

Country Status (18)

Country Link
US (1) US6395719B1 (no)
EP (1) EP0970695A1 (no)
JP (1) JP2002518329A (no)
KR (1) KR20010052891A (no)
CN (1) CN1305377A (no)
AU (1) AU751158B2 (no)
BR (1) BR9911220A (no)
CA (1) CA2335295A1 (no)
EA (1) EA200100039A1 (no)
HR (1) HRP20000862A2 (no)
HU (1) HUP0102506A3 (no)
IL (1) IL139015A0 (no)
NO (1) NO20006087D0 (no)
PL (1) PL344785A1 (no)
SK (1) SK18792000A3 (no)
TR (1) TR200003704T2 (no)
WO (1) WO1999065489A1 (no)
ZA (1) ZA200005887B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288108B1 (en) 1998-06-16 2001-09-11 Eli Lilly And Company Methods for increasing levels of acetylcholine
WO1999065489A1 (en) 1998-06-16 1999-12-23 Eli Lilly And Company Methods for increasing levels of acetylcholine
EP0976404A3 (en) * 1998-07-30 2001-06-27 Pfizer Products Inc. A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal
US20050232990A1 (en) * 2003-12-31 2005-10-20 Garth Boehm Donepezil formulations
GB0511003D0 (en) * 2005-05-28 2005-07-06 Univ Cardiff Screening and treatment of alzheimer's disease

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002097B1 (en) 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5554601A (en) 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US6489355B2 (en) 1993-12-01 2002-12-03 Eli Lilly And Company Methods of inhibiting the effects of amyloidogenic proteins
US5534526A (en) 1993-12-21 1996-07-09 Eli Lilly And Company Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome
US5441965A (en) 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
CA2176127A1 (en) 1993-12-21 1995-06-29 William Henry Walker Lunn Methods for the treatment or prevention of conditions associated with amyloidogenic reptides
US5462950A (en) 1993-12-21 1995-10-31 Eli Lilly And Company Methods of treating menstrual symptoms and compositions therefore
US5389670A (en) 1993-12-21 1995-02-14 Eli Lilly Company Methods of inhibiting the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder
US5552415A (en) 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
US5578613A (en) 1993-12-21 1996-11-26 Eli Lilly And Company Methods for inhibiting weight gain or inducing weight loss
US5604248A (en) 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5512296A (en) 1994-08-22 1996-04-30 Eli Lilly And Company Methods for inhibiting neuronal damage
PE44597A1 (es) 1995-02-28 1997-10-13 Lilly Co Eli Compuestos de benzotiofeno, productos intermedios, composiciones y procedimientos
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5731342A (en) * 1996-02-22 1998-03-24 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods
IL120269A0 (en) 1996-02-28 1997-06-10 Pfizer 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease
SK285312B6 (sk) 1996-06-07 2006-10-05 Eisai Co., Ltd. Polymorf (III) donepezil hydrochloridu, spôsob jeho výroby a terapeutický prostriedok s jeho obsahom
ZA982877B (en) 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
WO1999065489A1 (en) 1998-06-16 1999-12-23 Eli Lilly And Company Methods for increasing levels of acetylcholine
WO1999065309A1 (en) 1998-06-16 1999-12-23 Eli Lilly And Company Methods for increasing levels of acetylcholine

Also Published As

Publication number Publication date
KR20010052891A (ko) 2001-06-25
EP0970695A1 (en) 2000-01-12
JP2002518329A (ja) 2002-06-25
WO1999065489A1 (en) 1999-12-23
PL344785A1 (en) 2001-11-19
HUP0102506A3 (en) 2003-01-28
SK18792000A3 (sk) 2001-07-10
ZA200005887B (en) 2002-07-22
AU751158B2 (en) 2002-08-08
CN1305377A (zh) 2001-07-25
TR200003704T2 (tr) 2001-06-21
US6395719B1 (en) 2002-05-28
CA2335295A1 (en) 1999-12-23
IL139015A0 (en) 2001-11-25
EA200100039A1 (ru) 2001-06-25
BR9911220A (pt) 2001-03-06
HUP0102506A2 (hu) 2002-01-28
HRP20000862A2 (en) 2001-10-31
AU4333899A (en) 2000-01-05
NO20006087D0 (no) 2000-11-30

Similar Documents

Publication Publication Date Title
KR960704839A (ko) β-아밀로이드 단백질 생성 억제제(Inhibitors of β-amyloid protein production)
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
NO962568L (no) Anvendelse av PLA2 inhibitorer som behandling for Alzheimers sykdom
DE69833971D1 (de) Verfahren zur behandlung von alzheimerschen krankheit
EA199900490A1 (ru) СПОСОБЫ И СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ ВЫДЕЛЕНИЯ β-АМИЛОИДНОГО ПЕПТИДА И/ИЛИ ЕГО СИНТЕЗА
WO2003104273A3 (en) Therapeutic epitopes and uses thereof
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
NO20033617D0 (no) Fremgangsmåte for behandling av diabetes mellitus
LU91926I2 (fr) Belimumab et ses dérivés pharmaceutiquement acceptables (Benlysta®)
EA199900778A1 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И ИХ ИСПОЛЬЗОВАНИЕ ДЛЯ ИНГИБИРОВАНИЯ β-АМИЛОИДНОГО ПЕПТИДА
MXPA03010843A (es) Uso de derivados con azetidinona en el tratamiento de enfermedad de alzheimer.
MXPA04003245A (es) Hidroxipropilaminas.
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer&#39;s disease by enhancing plasmin or plasmin-like activity
NO970161L (no) Triazolforbindelser og anvendelse derav
MXPA04002785A (es) Aminas sustituidas para tratamiento de enfermedad de alzheimer.
MXPA04000338A (es) Diamindioles para tratamiento de enfermedad de alzheimer.
MXPA03011521A (es) Aminadioles para tratamiento de enfermedad de alzheimer.
BR0210392A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
WO2001091796A8 (en) Methods, compounds and compositions for treating gout
NO20006087L (no) Fremgangsmåter for å öke nivåer av acetylcholin
DE60230155D1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
MXPA03011502A (es) Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application